Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the impact of genetic variants of OATP 1B3 or MRP 2
on the systemic disposition of endogenously formed CCK-8 and to determine the influence of a
single-dose of the transporter inhibitor rifampin (600 mg) on the systemic disposition of
endogenously formed CCK-8. Endogenous CCK-8 secretion will be induced by a single-dose
standardized liquid mixed meal.